Prostate Cancer Daily

May 26, 2026

Videos

Peer-to-Peer Clinical Conversations

MEVPRO-3 Trial: Enzalutamide With or Without Mevrometostat in Metastatic Hormone-Sensitive Prostate Cancer - Neeraj Agarwal

Neeraj Agarwal

Neeraj Agarwal describes the MEVPRO-3 trial design.

View

Real-World Analysis of Genetic Testing Rates and Barriers in Metastatic Prostate Cancer - Pedro Barata

Pedro Barata

Neeraj Agarwal speaks with Pedro Barata about genetic testing in metastatic castration-resistant prostate cancer, focusing on real-world data from Flatiron and other databases.

View

Beyond the Abstracts

A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer - Beyond the Abstract

Association Between Baseline Prostate MRI PI-RADS Classification and Risk of Gleason Upgrade During Active Surveillance: A Systematic Review and Meta-Analysis - Beyond the Abstract

Conference Coverage

AUA 2026: Delayed Survival Benefit of Enzalutamide Plus Radium-223 in Metastatic Castration-Resistant Prostate Cancer: A Reconstructed Individual Patient Data Analysis of the PEACE-3 Trial

AUA 2026: Safety of Rucaparib versus Docetaxel or Second-generation Androgen Receptor Pathway Inhibitor Therapy for Patients with Metastatic Castration-resistant Prostate Cancer and a BRCA mutation in TRITON3

AUA 2026: Duration of Treatment Suspension Among All Randomized Patients in EMBARK

APCCC 2026: PSA Recurrence After Radiotherapy – When and How to React?

APCCC 2026: Real World Radium-223 Outcomes in Metastatic Castration-Resistant Prostate Cancer: Updated Spanish Tertiary Center Cohort to January 2024

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Bladder activity of different PSMA PET radioligands and impact of furosemide.

Real-world comparative effectiveness of apalutamide versus enzalutamide for prostate-specific antigen response in metastatic castration-sensitive prostate cancer.

Focal Signet Ring-Like Prostate Adenocarcinoma Detected on Microultrasound in the Setting of Negative Multiparametric Magnetic Resonance Imaging: A Case Report.

Moderate hypofractionated boost to the prostate with pelvic radiotherapy in high-risk prostate cancer (MOB-RT) - a phase 2 study: acute safety and quality of life outcomes.

Improving physical activity in men with prostate cancer through wearable devices and online education: Randomized controlled trial.

Baseline PSMA-ligand PET/CT as a predictive biomarker for early progression in metastatic castration-resistant prostate cancer patients undergoing [177Lu]Lu-PSMA-617 radioligand therapy.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Prostate Cancer Daily

Prostate Cancer

Login